

**Details of Research Experience as Principal Investigator during the last 10 years**

<b>Title of study</b>	<b>From</b>	<b>To</b>	<b>funding Agency</b>	<b>Grant ID</b>	<b>Grant Amount</b>	<b>Status: Completed/ Ongoing</b>	<b>Project Summary indicating significant scientific contribution in case of completed project OR Background, objectives, Methods, Results in case of ongoing projects</b>	<b>No. of publications/ patents/ copyrights)</b>
To identify COVID perturbed genes and immune-repertoire network in diabetes and obesity associated severe infections	2021	2024	<b>ICMR</b>	13 <sup>th</sup> clinical Research Group meeting, ICMR COVID clinical research group (CRG)		ongoing		
To study the ultra and molecular changes in bone of T2DM and strategy to overcome fragility bone quality and quantity, mechanical properties, remodeling indices as well as genomic data in T2DM	022	2025	<b>ICMR DHR</b>	Gia/2019/000111/PRCGIA	1.5 crore	ongoing		

Evaluation of Polycomb repressive complex 2 target genes as potential epigenetic regulators of sporadic primary hyperparathyroidism	Feb 2021	Jan 2024	ICMR, New Delhi	2020-3486/20	37 lakhs	Ongoing		
Development of Nano-enabled Teriparatide-Loaded Pharmaceutical Product for Osteoporosis: An approach to reduce the dose frequency with better patient compliance therapeutic efficacy	Sept 2019	August 2022	ICMR, New Delhi	35/1/2019-Nano/BMS	49 Lakh	Ongoing	In this project we attempt to introduce novel drug delivery system in the form of intramuscular sustained release depot or implant gel formulation by making use of lipid based nanocarriers which will help to reduce the dose and dosage frequency which eventually decrease in overall cost of therapy thus increase the patient compliance.	Ongoing
Penetrance of susceptibility and protective genes in familial clustering of Type 1 diabetes and its co association with celiac disease.	August 2019	July 2021	ICMR, New Delhi (Task Force Project)		70 lakhs	Ongoing	Current study is planned to study the allele polymorphism of HLA class I and class II loci in families affected with T1D and CD with a putative	Ongoing

							target to delineate susceptible and protective genotypes for familial clustering of these diseases and their co-occurrence in two geographically and ethnically different regions of India.	
Identification of Potential Epigenetic Biomarkers for Detection and Diagnosis of Primary Hyperparathyroidism	July, 2018	June 2021	<b>DST-SERB, New Delhi</b>		37 lakhs	Ongoing	In this study the altered expression of transcription factors (GCM2, GATA3 and PAX1) with epigenetic modifications such as DNA methylation in promoter regions of genes and histone methylation especially H3K9me3 and H3K27me3 affect their binding to CASR promoter region that decrease its expression. Treatment with inhibitors of DNA or histone methylation could reverse these alterations and would normalize the expression of these	Ongoing project

							genes in parathyroid culture or cell line.	
Expression profiling of Mitogen activated protein Kinase Signalling molecules in patients with sporadic primary hyperparathyroidism	April 2015	March 2017	<b>Endocrine Society of India (ESI)</b>		4 lakh	Completed	Our study showed that ERK pathway is highly dysregulated MAPK pathway in sporadic Parathyroid tumors. We also showed that in downstream of ERK pathway cell cycle regulators are highly dysregulated which might lead to higher cell proliferation during parathyroid tumorigenesis.	One Publication
To study the methylation status of CDKN2A, CDKN2B and RASSF1A in patients with primary hyperparathyroidism	April 2014	March 2016	<b>Intramural (PGIMER)</b>		2.8 Lakh	Completed	Promoter Hypermethylation in responsible of down expression of CDKN2A, CDKN2B and RASSF1A in sporadic primary hyperparathyroidism.	One Publication
Identification of differentially expressed proteins in parathyroid tumors and their clinical correlation with the disease “.	October 2012	Sept. 2015	<b>ICMR, New Delhi</b>		20 lakhs	Completed	Comparative proteomics revealed that a total of 206 proteins (74 upregulated and 132 downregulated) were differentially expressed in	Two publications

							<p>parathyroid adenoma. Proteins belonged to a diverse protein family such as enzymes, transcription factors, cell signalling, cell adhesion, cytoskeleton proteins, receptors, and calcium-binding proteins. The differentially expressed proteins were found to be associated with MAPK, PLC, PI signalling pathways, and with chromatin organization.</p>	
Expression of vitamin D receptor and Calcium Sensing Receptor in patients with Primary Hyperparathyroidism and its correlation with clinical outcome.	Oct 2010	Sept. 2013	ICMR, New Delhi		18 lakhs	Completed	<p>Our study showed the reduced expression of Calcium sensing receptor and vitamin D Receptor and increased expression of cyclin D1. We also showed that the reduced expression of VDR and CASR is not due to hypermethylation in their promoter region.</p>	Two publications

